Journal
Journal of Clinical Investigation
Publication Date
10-17-2022
Volume
132
Issue
20
First Page
e163107
Document Type
Open Access Publication
DOI
10.1172/JCI163107
Rights and Permissions
Nelvagal HR, Eaton SL, Wang SH, Eultgen EM, Takahashi K, Le SQ, Nesbitt R, Dearborn JT, Siano N, Puhl AC, Dickson PI, Thompson G, Murdoch F, Brennan PM, Gray M, Greenhalgh SN, Tennant P, Gregson R, Clutton E, Nixon J, Proudfoot C, Guido S, Lillico SG, Whitelaw CBA, Lu JY, Hofmann SL, Ekins S, Sands MS, Wishart TM, Cooper JD. Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep. J Clin Invest. 2022 Oct 17;132(20):e163107. doi: 10.1172/JCI163107. © 2022, Nelvagal et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License
Recommended Citation
Nelvagal, Hemanth R.; Wang, Sophie H.; Eultgen, Elizabeth M.; Takashash, Keigo; Le, Steven Q.; Nesbitt, Rachel; Dearborn, Joshua T.; Dickson, Patricia I.; Sands, Mark S.; Cooper, Jonathan D.; and et al., "Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep." Journal of Clinical Investigation. 132, 20. e163107 (2022).
https://digitalcommons.wustl.edu/oa_4/592
Supplemental Data Set 1.xlsx (25 kB)
Supplemental Data Set 2.xlsx (55 kB)
Supplemental Data Set 3.pdf (4792 kB)
